The promise of neoadjuvant immunotherapy and surgery for cancer treatment.

The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clin Cancer Res. 2019 Apr 30;: Authors: O'Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL Abstract Cancer immunotherapies utilizing immune checkpoint inhibitors (ICIs) have demonstrated durable efficacy in a proportion of patients with advanced/metastatic cancers. More recently, the use of ICIs for the adjuvant treatment of patients with surgically resectable melanoma have also demonstrated efficacy by improving relapse-free survival and in the case of ipilimumab (anti-CTLA-4) also improving overall survival. While promising, the effective scheduling of surgery and immunotherapy and its duration is not well elucidated. Recent preclinical studies suggest that surgery followed by adjuvant therapy might be suboptimal as compared to an approach in which immunotherapy is applied before surgery (neoadjuvant immunotherapy). Encouraging findings from early phase clinical trials in melanoma, NSCLC and glioblastoma support the idea that neoadjuvant immunotherapy might have improved clinical efficacy over an adjuvant application. In this review we discuss the existing rationale for the use of neoadjuvant immunotherapy, its apparent strengths, weaknesses, and implications for the design of future clinical trials. PMID: 31040150 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research

Related Links:

CONCLUSIONS: Although we found that MSI-H was uncommon (0.9%) in TNBCs, potential targets for ICIs exist in TNBCs. Therefore, MSI-H breast cancer patients should be picked up using not only conventional methods but also platforms for comprehensive genomic profiling. PMID: 31907878 [PubMed - as supplied by publisher]
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
Publication date: Available online 3 January 2020Source: Seminars in Cancer BiologyAuthor(s): Kelly Olino, Tristen Park, Ntia AhujaAbstractAdvances in immunotherapy, most notably antibodies targeting the inhibitory immune receptors cytotoxic T-lymphocyte associated protein 4 (CTLA-4/CD152), programmed death protein 1 (PD-1/CD279) and programmed death-ligand 1 (PD-L1/B7H1/CD274) have become effective standard therapies in advanced malignancies including melanoma,1–4 merkel cell carcinoma5, urological cancers6–8, non-small cell lung cancer9–11, mis-match repair (MMR) deficient tumors12, and Hodgkin lymphoma...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Conclusions: Sebaceous carcinoma currently has few effective adjuvant treatment options. The expression of PD-1, PD-L1, and PD-L2 on infiltrating immune cells and PD-L2 on tumor cells restrains T-cells from full activation and proliferation, therefore limiting the antitumor effect of T-cells, tipping the balance toward unopposed tumor progression. Consequently, PD-1 or PD-L1 inhibitors may have a role in sebaceous carcinoma treatment. Given the prevalence of PD-L2 expression in sebaceous carcinoma and the lack of PD-L2 blockade therapy available, PD-1 blockade may provide benefit over PD-L1 inhibitors. PD-1 blockade in c...
Source: Ophthalmic Plastic and Reconstructive Surgery - Category: Opthalmology Tags: Original Investigations Source Type: research
AbstractDammarenolic acid (DA) is an A-seco-dammarane triterpenoids, isolated fromDipterocarpus alatus resin. DA was modified including reactions of esterification and amination with heterocyclic amines andl-amino acids. The structures of new compounds were confirmed by MS,1H NMR, and13C NMR spectroscopic analyses and their activities againstα-glucosidase and acetylcholinesteras were studied. The cytotoxic activity of DA was screened using a broad panel of 60 human cancer cell lines and it has cytotoxic effect for a variety of human tumor cell lines (leukemia, non-small cell lung cancer, colon cancer, CNS cancer, mel...
Source: Medicinal Chemistry Research - Category: Chemistry Source Type: research
Authors: Agrawal L, Bacal A, Jain S, Singh V, Emanuele N, Emanuele MA, Meah F Abstract Immune checkpoint inhibitors (ICPIs) are novel drugs in the field of oncology however carry the risk of immune related dermatologic, gastrointestinal, and endocrine side effects which can be fatal. These new innovative immunoregulatory drugs have intertwined the fields of oncology and endocrinology. CTLA-4 and PD-1 are co-inhibitory receptors on T cells that turn the T cell "off" when binding to receptors on APCs. Tumor cells can also carry receptors for CTLA- and PD-1. By rendering T cells inactive, tumor cells can eva...
Source: Postgraduate Medicine - Category: Internal Medicine Tags: Postgrad Med Source Type: research
ConclusionPD-L1 expression in TILs,but not in tumor cells,was a poor prognostic factor in TNBC. These data provide further impetus for assessing immunotherapy in TNBC, in view of the clinical significance of the expression of PD-L1(SP142) in TNBC.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
CONCLUSION: Our observations demonstrate that the Idylla cartridge for the EGFR, KRAS and BRAF mutations is highly accurate, rapid and has a limited hands-on time compared with next-generation sequencing. PMID: 31296605 [PubMed - indexed for MEDLINE]
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Pathol Source Type: research
DiscussionThe POPCORN study provides a unique platform for translational research to determine the mechanism of action of a novel proposed combination immunotherapy for cancer.Trial registrationProspectively registered on Australian New Zealand Clinical Trials Registry (ACTRN12618001121257) on 06/07/2018.
Source: Trials - Category: Research Source Type: clinical trials
Publication date: Available online 11 December 2019Source: Best Practice &Research Clinical Endocrinology &MetabolismAuthor(s): Giusy Elia, Silvia Martina Ferrari, Maria Rosaria Galdiero, Francesca Ragusa, Sabrina Rosaria Paparo, Ilaria Ruffilli, Gilda Varricchi, Poupak Fallahi, Alessandro AntonelliAbstractAnticancer immunotherapy, in the form of immune checkpoint inhibition (ICI), is a paradigm shift that has transformed the care of patients with different types of solid and hematologic cancers. The most notable improvements have been seen in patients with melanoma, non-small-cell lung, bladder, renal, cervical, u...
Source: Best Practice and Research Clinical Endocrinology and Metabolism - Category: Endocrinology Source Type: research
Conditions:   Melanoma;   Non-Small Cell Lung Cancer Interventions:   Other: Standard-of-care procedures;   Other: Study procedures Sponsor:   Prof.dr. E.G.E. de Vries Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Clinical Trials | Immunotherapy | Melanoma | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Skin Cancer | Study | Yervoy